NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

UK drugmakers, government agree renewed revenue clawback scheme

Published 20/11/2023, 13:26
© Reuters. Pharmaceutical tablets and capsules are arranged on a table in this picture illustration taken in Ljubljana August 20, 2014. Picture taken August 20.   REUTERS/Srdjan Zivulovic
LLY
-
ABBV
-

By Ludwig Burger

(Reuters) -Britain's pharmaceutical industry and the government have agreed terms to renew a medicines access scheme that requires the companies to pay back part of their drug revenue generated from the national health service, they said on Monday.

The Association of the British Pharmaceutical Industry (ABPI) said in a joint statement that the scheme agreed with the government and National Health Service (NHS) England, will run for five years until end-2028.

The Department of Health and ABPI said that the clawback deal would save the NHS 14 billion pounds ($17.5 billion) over the five years in medicines costs, while giving patients access to "the latest lifesaving treatments more consistently".

ABPI has said that in 2021, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) rebates - or clawback - meant companies paid around 5% of their revenue back to the NHS, but in 2022 it rose to 15% and in 2023 to 26.5% due to increased NHS demand related to the COVID-19 pandemic.

As a result, U.S. pharmaceutical majors AbbVie (NYSE:ABBV) and Eli Lilly (NYSE:LLY) in January withdrew from the scheme. Trade body ABPI in February called for the government to overhaul the programme.

Under the old scheme, overall company revenues from NHS expenditure on branded drugs, some of which included off-patent generic drugs, that exceeded 2% annual growth from a 2014 base year were subject to a clawback by the government.

Based on complex deal terms, the annual growth rate above which clawbacks kick in will rise to about 6.1% through 2028, according to ABPI.

More terms were introduced in the scheme to favour younger drugs, to encourage new drug development, and have a higher burden on older drugs that still command high margins for the manufacturers.

© Reuters. Pharmaceutical tablets and capsules are arranged on a table in this picture illustration taken in Ljubljana August 20, 2014. Picture taken August 20.   REUTERS/Srdjan Zivulovic

The estimated 14 billion pounds in future multi-year clawbacks would be larger than what was paid over the previous five years but the industry would still participate in an expected faster overall drug market growth in Britain, said ABPI.

($1 = 0.8025 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.